Protara Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $227.5M
- Price
- $3.85
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.28%
- Volume
- 238.4K
About
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Quick stats
Shares outstanding59.1M
Computed float58.0M
Float / shares98.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001359931
Websitehttps://www.protaratx.com
AI Summary
AI-generated1/16
standardbullishearnings
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Protara reported $161.9 million in cash, cash equivalents and investments, expected to fund planned operations into 2028, alongside progress across its late-stage pipeline.
Interim data from the STARBORN-1 trial demonstrated an 83% clinical success rate for TARA-002 in Lymphatic Malformations, with a BLA submission planned for the second half of 2027.
For the second quarter, the company recorded a net loss of $21.7 million, or $0.36 per share, driven primarily by increased clinical trial costs and personnel expenses.